Pharma
1 article
Biogen and Denali's LRRK2 Inhibitor Flops in Phase II Parkinson's
Trial The Problem Parkinson's disease drug development has hit another wall. • The trial enrolled 648 patients aged 30-80 across multiple sites, testing the sm...
1 article
Trial The Problem Parkinson's disease drug development has hit another wall. • The trial enrolled 648 patients aged 30-80 across multiple sites, testing the sm...